Viatris Inc.

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • Generic Drugs
    • Specialty Pharmaceuticals

Other Names/Subsidiaries

  • Acton Pharmaceuticals
  • Agila
  • Antula Healthcare
  • Bertek
  • Dow B. Hickham
  • Famy Life Sciences
  • Generics (UK)
  • Jai Pharma
  • Madaus Pharma
  • Meda Pharmaceutical
  • Mylan
  • Mylan Laboratories (formerly Matrix Laboratories Limited)
  • Mylan Pharmaceuticals
  • Mylan Specialty (formerly Dey Pharma)
  • Oyster Point Pharma
  • Rottapharm
  • Synerx Pharma
  • UDL Laboratories
See more in Biomedtracker

Latest on Viatris Inc.

Scrip

Asia Deal Watch: Daiichi Sankyo Teams With Nosis On Extrahepatic RNA Therapies

 
• By Joseph Haas, Jung Won Shin, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Start-Up Nosis Partners Its AI Pl

Generics Bulletin

Viatris ‘Actively Launching’ Glucagon As It Looks To Deliver On Pipeline Promise

 
• By Dean Rudge

Viatris says its US generic glucagon 1mg/vial injectable is “actively being launched,” as the firm looks to deliver on its long-promised string of complex injectables going into a challenging 2025. Ne

Generics Bulletin

Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025

 
• By Dean Rudge

The US Food and Drug Administration warning letter and import alert currently blocking export of seven of Viatris’ non-shortage-related products from its oral finished dose manufacturing facility in I

Scrip

Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan

 
• By Mandy Jackson

BridgeBio Oncology Therapeutics (BBOT), the cancer drug company spun out of rare disease-focused BridgeBio Pharma in May 2024 with $200m in venture capital financing, announced on 28 February that it